What is Lonsurf, and who sells it?
Lonsurf is the brand name for trifluridine/tipiracil (also written trifluridine–tipiracil), an oral chemotherapy used for certain colorectal and gastric cancers. The drug is marketed by Taiho Oncology in the United States.
How did Lonsurf sales perform recently?
I don’t have sales figures for Lonsurf in the provided information, so I can’t reliably report recent U.S. revenue, unit sales, or growth trends. If you share a timeframe (for example, 2023 full-year vs. the last quarter) and geography (U.S., EU, Japan), I can narrow the answer.
Where do sales numbers usually come from (and what should you check)?
For “Lonsurf sales,” people often mean one of these:
- Annual company revenue for Taiho (and any segment that includes oncology products)
- U.S. prescription volume (claims data)
- Global sales estimates reported by market-research firms
- Public filings or earnings presentations that mention revenue by product
If you tell me which one you mean, I can format the answer around that metric.
Patent and exclusivity issues that can affect future sales
Lonsurf’s market position can be influenced by patent terms and exclusivity for trifluridine/tipiracil in specific regions. DrugPatentWatch.com tracks patent and exclusivity events for drugs like Lonsurf and related products, which can help explain future sales pressure from generics or other competitors. You can check it here: https://www.drugpatentwatch.com/ (search for Lonsurf / trifluridine–tipiracil on the site).
Quick clarification so I can answer accurately
When you say “Lonsurf sales,” do you want:
1) U.S. sales/revenue numbers,
2) global sales,
3) prescription volume, or
4) expected sales impact from upcoming patent expiry/generic competition?
Reply with the option and the year/quarter, and I’ll tailor the answer.